



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- August 09, 2023

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

BSE Script Code: 531599

NSE Symbol: FDC

Sub: Press Release on Q1 - FY 2023-24 Results.

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter ended June 30, 2023.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

VARSHARAN
I RAJARAM
KATRE

Digitally signed by
VARSHARANI
RAJARAM KATRE
Date: 2023.08.09
20:36:16 +05'30'

Varsharani Katre

Company Secretary & Compliance Officer

M No.: FCS-8948




FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q1FY24 results

Mumbai, 9th Aug 2023: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ended 30th June 2023.



Consolidated Q1FY24 FDC reported

Rs. in crores	Q1FY24	Q1FY23	YoY Growth %
Operating Revenue	536	495	8.4%
EBITDA	122	78	56.4%
EBITDA %	22.7%	15.8%	
PBT	141	87	61.7%
PAT	110	71	55.4%
EPS (Rs.)	6.62	4.23	56.6%

Commenting on the results;

We are pleased to announce that we have achieved growth across all our business segments in the current quarter. Our domestic business segment reported growth of 6% during the quarter, albeit under some price pressure. Notably, our Export Formulation and API business segments exhibited robust year-over-year growth of 19%.

Furthermore, we are delighted to report that our margins and profits have shown improvement which is attributed due to improved sales realization and an increase in other income. We remain focused on sustaining and building upon these advancements in the upcoming periods.



CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
 Tel.: +91-22-3071 9100 - 399 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2678 6393 / 8123 / 1912
 E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
 Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
 E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

Business-wise Sales Performance

₹ Cr	Q1FY24	YoY Grw %
Operating Revenue	536	8.4%
India Formulations	445	5.7%
US Formulations	36	29.8%
Emerging Markets	33	16.5%
API Sales	22	26.9%

India Market:

The sale of branded formulations in India for Q1FY24 was Rs. 445.1 crores, with a growth of 5.7% on YoY and 31.7% on QoQ. Overall sales in the Indian market accounted for 83% of total consolidated sales for the quarter.

As per secondary sales data by IQVIA for the quarter ended June 30, 2023, the Company delivered YoY growth of 7.9% compared to the Indian Pharmaceutical Market (IPM) growth of 8.5% YoY. Electral has moved up to 26th in IPM in MAT Jun'23 as compared to 32nd in the same period last year.

Further, the company was the 2nd fastest growing corporate at MAT Jun'23 among the Top 25 corporates.

Export Formulations Market:

Formulation Sales in the Export market were Rs. 68.87 crores in Q1FY24, up by 23% over YoY and lower by 9.2% over QoQ and accounted for 13% of total consolidated sales. The main contributor to the growth is the USA market which accounts for 52% of total Export Formulations Sales.

During the quarter, the Company filed one ANDA for Pilocarpine Hydrochloride Ophthalmic Solution USP, 1%, 2% and 4%.

API Business:

API Sales were Rs. 22.41 crores in Q1FY24, up by 26.9% over YoY and up by 6.4% over QoQ and accounted for 4% of total consolidated sales.



ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

